Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years - including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc. (Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Dr Tihamer Orban MD MRCPCH is a world-leader in the field of the immunological mechanisms underlying T1DM. His medical degree and board certification in Paediatrics were from the medical school of Szent-Gyorgyi Albert University, Hungary. He worked at the Joslin Diabetes Center, Harvard from 1993 to 2011. His career as a Translational Clinical Investigator has been devoted to the research, discovery and clinical evaluation of novel therapies for T1DM. He was previously Principal Investigator at three major US nationwide networks dedicated to ameliorate autoimmunity including T1DM (TrialNet, Immune Tolerance Network and Autoimmune Centre of Excellence at Harvard, all funded by National Health Institute of USA). He was the Chairman of the Safety Monitoring Committee of the TrialNet for many years overseeing safety of several multicentre clinical trials. Whilst at the Joslin Diabetes Center, Boston, USA, he ran several clinical trials, and was instrumental in designing and executing them. He initiated and chaired a phase 2 multicentre clinical trial using abatacept in T1DM patients. The results were published in The Lancet, with a joint commentary titled "New hope for immune therapy in Type 1 diabetes".

Dr Tihamer Orban is the President and Chief Scientific Officer of the Company. He is responsible for overseeing and guiding the management and governance of the Company. He provides visionary and strategic leadership to ensure that the company is progressing in accordance with its missions. As Chief Scientific Officer, he also has special responsibility for managing the scientific development of the AIM therapy and leading on future research and development.

Professor Piers Daubeney MA DM FRCP FRCPCH DCH trained in medicine at Oxford University and St Thomas' Hospital gaining Honours in Therapeutics and Clinical Pharmacology. He specialised as a paediatric cardiologist working at the Royal Brompton Hospital and is Professor of Practice (paediatric cardiology) at Imperial College. He has written more than 50 scientific papers and edited 2 books. He jointly founded and is also CEO of The Congenital and Children's Heart Centre (www.childrensheartcentre.com) providing private medical and surgical care to children and adults with congenital heart disease with large national and international referral base.

His expertise lies in the development of new drugs that promote child health and he has extensive experience of large multicentre drug studies. He is a member of the UK Medicines for Children Clinical Research Network and previously the British Paediatric Surveillance Unit at the Royal College of Paediatrics and Child Health.

Dr Piers Daubeney is the Chief Executive Officer of the Company and is responsible for the day to day running of the Company as well as future business development and strategy.

Dr Nara Daubeney MBBS MEd (Surg) DIC MRCS(Eng) DLO is an adult and paediatric ENT surgeon and honorary senior clinical lecturer at Barts NHS trust and Queen Mary Univerity London. She qualified at Imperial College and Charing Cross Hospital and is a member of the Royal College of Surgeons. She is passionate about research having studied for a PhD at Imperial College and has considerable expertise in autoimmunity particularly nasal. She jointly founded and is director of The Congenital and Children's Heart Centre (www.childrensheartcentre.com) providing private medical and surgical care to children and adults with congenital heart disease.

Dr Nara Daubeney is the Chief Operating Officer of the Company and is responsible for the regulatory, tax, compliance, communication and accounting aspects of the Company.

Dr Heyam Jalahej MD is a Board Certified Paediatrician and Surgeon, and completed her medical training at Szent-Gyorgyi Albert University, Hungary. She brings significant expertise in Ethics and Clinical Compliance, and trial design. From 2001 to 2011 she worked with the Type 1 diabetes research team at the Joslin Diabetes Center, Harvard, where she successfully brought to completion several multiple complex phase 1 and phase 2 clinical trials in the field of diabetes. Her expertise in pre-clinical and translational clinical research programmes and their coordination played a key role in developing a novel AIM therapy for T1DM. She shepherded the approval process from concept through FDA investigational drug approval to the successful completion of the Phase 1 clinical trial.

Dr Heyam Jalahej is the Chief Medical Regulatory Officer of the Company and is responsible for compliance with regulatory and logistic aspects of development of therapeutic and diagnostic modalities including the AIM therapy development.

Jon started his scientific career in academia as a member of scientific staff in the Biochemistry Department, Imperial College. Jon moved to the Medical Research Council Toxicology Unit as a Senior Scientific Officer working on mechanisms of carcinogenesis. Jon joined Cambridge Antibody Technology, (CAT), in 1992 as a Senior Scientist, working on multiple drug discovery projects. After a few years, Jon then joined a new team establishing the process development group before eventually moving across into operational management. CAT merged with Medimmune (a wholly owned subsidiary of Astra Zeneca) in 2006 where Jon latterly held the post of VP, Site General Manager a position he held for some years. At Medimmune Jon led the multidisciplinary site operations of the Cambridge R & D facilities, a site of some 800 staff.

In 2021 Jon joined Iontas, a world leading contract research organisation in the antibody engineering field, as Chief Operating Officer.

Jon is the current Chair of the Board of One Nucleus and holds several other NED appointments including, Stevenage Bioscience Catalyst. Jon has a MPhil in molecular biology/cellular pathology, is a Chartered Biologist and Fellow of the Royal Society of Biology. Jon is also fellow of the Royal Society of Arts and Manufacturing and the Institute of Directors.